Abstract
Background
Our previous study demonstrated that an up-regulation of the Brain-Derived Neurotrophic Factor (BDNF) signaling pathway is involved the mechanism causing the recurrence of triple negative breast cancer. The aim of this study is to investigate the effects of commonly used Chinese medicinal herbs on MDA-MB-231 and HUVEC cells and how they interact with BDNF.
Methods
Human TNBC MDA-MB-231 cells and human endothelial HUVEC cells were used to explore the effect of commonly used Chinese herbal medicines on cancer cells alone, on endothelial cells alone and on cancer cell/endothelial cell interactions; this was done via functional studies, including migration and invasion assays. Furthermore, Western blot analysis and real-time PCR investigations were also used to investigate migration signal transduction, invasion signal transduction, and angiogenic signal transduction in these systems. Finally, the effect of the Chinese medicinal herbs on cancer cell/endothelial cell interactions was assessed using co-culture and ELISA.
Results
In terms of autoregulation, BDNF up-regulated TrkB gene expression in both MDA-MB-231 and HUVEC cells. Furthermore, BDNF enhanced migration by MDA-MB-231 cells via Rac, Cdc42 and MMP, while also increasing the migration of HUVEC cells via MMP and COX-2 expression. As measured by ELISA, the Chinese herbal medicinal herbs A. membranaceus, P. lactiflora, L. chuanxiong, P. suffruticosa and L. lucidum increased BDNF secretion by MDA-MB-231 cells. Similarly, using a co-culture system with MDA-MB-231 cells, A. membranaceus and L. lucidum modulated BDNF-TrkB signaling by HUVEC cells.
Conclusion
We conclude that BDNF plays an important role in the metastatic interaction between MDA-MB-231 and HUVEC cells. Some Chinese medicinal herbs are able to enhance the BDNF-related metastatic potential of the interaction between cancer cells and endothelial cells. These findings provide important information that should help with the development of integrated medical therapies for breast cancer patients.
Electronic supplementary material
The online version of this article (doi:10.1186/s12906-017-1909-7) contains supplementary material, which is available to authorized users.
Keywords: BDNF, Breast cancer, Endothelial cell, Chinese herbal medicine
Background
Breast cancer is a common female cancer worldwide and is also common in Taiwan [1, 2]. Triple negative breast cancer (TNBC), which comprises 15% of all breast cancers, is characterized by its early occurrence in younger women and its aggressive behavior, including a high recurrence rate and distant metastasis, Owing to a lack of specific receptors, TNBC shows strong resistance to chemotherapy, hormone therapy and targeted therapy [3]. Although many biomarkers associated specifically with various subtypes of TNBC have been identified [4] and several targeted therapies, such as luminal androgen receptor (LAR) and tyrosin kinase inhibitors, have been investigated in clinical trials [5, 6], long-term outcomes indicate that they seem to have limit usefulness when treating TNBC patients [7].
Brain-derived neurotrophic factor (BDNF) is a member of the “neutrophin” family. This protein supports the survival of existing neurons, encourages the growth of new neurons, helps with the creation of new synapses [8] and is involved in neural development/regeneration, muscle repair/regeneration, and differentiation [9]. Previously, BDNF and its related receptor signaling system (BDNF/TrkB) have been shown to play important roles in the regulation of cell proliferation and metastasis across many types of cancer, including colon cancer, lung cancer and cancer of the brain [10, 11]. In addition, BDNF is found to increase cell viability and is associated with a reduction of the apoptosis of breast cancer [12]. The expression of BDNF mRNA has been shown to correlate with increased nodal positivity and the local recurrence rate; furthermore, treatments with anti-BDNF and anti-TrkB-T1 antibodies result in tumor growth inhibition in tumor-bearing mice, which suggests that that this protein can be used as a marker to predict adverse pathological and clinical outcomes related to breast cancers [13]. Although controversy still exits as to the exact role of BDNF in tumor suppression and promotion, information concerning BDNF-related cancer-endothelial cell interactions are lacking [14].
There is an increasing trend whereby patients with breast cancer seek integrative medicine in order to relieve their discomfort during the conventional modern medical therapies used to treat their disease; these symptoms include hot flushes, cancer-related fatigue and insomnia [15]. The prevalence of the use of integrative therapy among women with breast cancer is around 75% for patients in non-Asian areas [16], and around 36% to 40% for Taiwanese patients [17], although these figures are likely to be underestimates. Unfortunately, many patients with breast cancer who use integrative therapies are not aware of the potential adverse effects of these additional treatments. For examples, the consumption of many Chinese herbal extracts can have an up-regulatory effect on the gene expression levels of ER and HER2 in vitro [18] as well as interacting with the effects of tamoxifen in vivo [19].
Our previous study targeting the molecular mechanisms that occur in paired tumor specimens obtained from patients with and without recurrence, have suggested that the BDNF signaling pathway is involved in the up-regulation of genes that are present in stage II and stage IIIA recurrent breast cancer [20]. Since cancer metastasis is highly related to tumor recurrence in TNBC, further investigation of the effects of Chinese medicinal herbals on BDNF-related metastatic potential, specifically on the interaction between cancer cells and endothelial cells, is likely to provide important information for TNBC patients when they have undertaken integrative therapies to alleviate their discomfort. Accordingly, the aim of this study was to investigate the effects of Chinese medicinal herbs on the BDNF-related interaction between MDA-MB-231 and HUVEC cells.
Methods
Cell line and reagents
The human triple negative breast cancer cell line MDA-MB-231 (ER-low, PR-low and HER2-low) was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and was maintained in F12 MEM (NO.12400–024,Gibco, NY,USA) supplemented with 10% FBS, 2 mM L-glutamine and penicillin/streptomycin and cultured at 37 °C in a humidified atmosphere containing 5% CO2. The human umbilical vein endothelial cell line (HUVECs) (BCRC No.H-UV001) was obtained from the Taiwan Medical Cell and Microbial Resources, Food Industry Research Development Institute, Taiwan, and was cultured in Medium 200 supplemented with low serum growth supplement (Invitrogen, Carlsbad, CA, USA). Cells at passages from 3 to 10 were used for all experiments. Recombinant human BDNF (PeproTech, Rocky Hill, NJ, USA) was used as a positive control and was purchased commercially.
Preparation of Chinese herbal extracts
Nine Chinese single herbs were used in this study. They were Scutellariae baicalensis, Astragulus membranaceous, Salviae miltiorrhizae, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Anemarrhenae rhizome, Paeonia suffruticosa, and Ligustrum lucidum. Chinese herbal extracts of these plants, denoted here as CHEs, were obtained from a GMP company (Sun Ten Pharmaceutical Co, Ltd., Taiwan) and had been authenticated by Ministry of Health and Welfare, Taiwan. The voucher specimens were prepared as water extracts of the CHEs by the company, which followed the standard GMP procedures in order to obtain compositions similar to those used clinically. The contents of the CHEs were standardized using high performance liquid chromatography (Additional file 1) [18]. To decrease any confounding effect caused by the presence of lipopolysaccharide contamination during the herbal preparation, polymyxin B (10 μg/mL) was administration routinely during each experiment. The protocol for the herbal treatment of the MDA-MB-231 and HUVEC cell lines and the evaluation parameters are shown in Fig. 1.
Measurement of BDNF levels
The level of BDNF in the culture medium was evaluated by ELISA using a commercially available protocol (Quantikine ELISA Human BDNF). In brief, MDA-MB-231 (4 X105/well in a six-well plate) cells were cultured for 1 day, which was followed by washing with PBS and the addition of low serum F-12 DMEM (0.1% FBS) with/without herbal extract treatment for 24 h and 48 h. Next the cultured medium or the conditioned medium was collected and centrifuged (300 x g) for 5 min. The level of BDNF in the supernatant from the medium was then measured by ELISA, and normalized against the cell number for CHE treatment.
Cell migration assay
In vitro cell migration assays were carried out on either the MDA-MB-231 cells or the HUVEC cells. These were performed using a cell culture insert (NO.80209, ibidi, Munich, Germany). In brief, 2 × 104 cells were seeded into the insert on a 3.5 cm Petri dish overnight, which was followed by low serum (1% FBS) starvation for 24 h. Following this, the cells were washed with PBS and the inserts removed. Next the cells were allowed to continue to be cultured either with or without herbal extract treatment. After a 24 h-incubation, the migrating cells were examined under a light microscope and photographed. The percentage of migratory cells (or the area) was calculated by comparing the treated group with the vehicle group. Neutralizing antibody against BDNF (GTX 16327, GeneTex, Inc., San Antonio, Texas, USA), non-specific antibody regarding BDNF (normal rabbit serum) and TrkB receptor inhibitor (GNF5837, MedChem Express, NJ, USA) were used to inhibit the BDNF-related migration activity associated with the MDA-MB-231 culture conditioned medium.
Transwell co-culture assays to assess the chemotaxic interaction between cancer cells and endothelial cells
MDA-MB-231 cells with a density of 8 × 104 cells/well were cultured in the upper chamber (for the invasion assay) or lower chamber (for the chemotaxic interaction assay) of a Transwell system (ThinCertTM cell culture inserts, 24 well, 8 μm, Greiner bio-one, Switzerland) for 1 d and this was followed by replacement of the culture medium with low serum (0.1% FBS) F-12 DMEM with/without each of the Chinese herbal extracts (1 μg / mL) for another day. Next HUVECs with a density of 5 × 104 cells/well were cultured in the upper chamber (for the chemotaxic interaction assay), which was placed onto the above-mentioned pretreated lower chamber. For invasion assay, MDA-MB-231 cells were cultured in the upper chamber with a reduced concentration of matrix gel (50 μg / mL/well). After 9 h of co-culture, the cells on the reverse side of upper chamber membrane were fixed and stained with 2% crystal violet for 10 min, then washed and photographed. The migrating cells were examined under a light microscope and photographed. The percentage of migrating or invasion cells was calculated by comparing the experimental group against the vehicle group.
Western blotting analysis
Cultured MDA-MB-231 and HUVECs were lysed in a buffer containing 150 mM KCl, 10 mM Tris pH 7.4, 1% Triton X-100, phosphatase inhibitor and protease inhibitors cocktail (Complete Mini; Roche, Mannheim, Germany). The protein concentration of each cell homogenate was then measured using the Bradford’s method [21]. Next 30 μg of each protein sample was loaded onto a gel and the proteins separated by 10% SDS-PAGE, after which the separated proteins were transferred onto a nitrocellulose membrane (Hybond-C; Amersham Biosciences, NJ, USA). The membrane was then blocked with 5% bovine serum albumin, which was followed by probing with a series of specific primary antibodies against VEGFA (Genetex, GTX 102643), TrkB (BD, 610,101), BDNF (Genetex, GTX62495), COX-2(Cayman 160,112), MMP2 (Cell Signaling, #13132), MMP9 (Cell Signaling, #13667), p-Rac1/cdc42 Ser71 (Cell Signaling #2461), Rac1/2/3 (Cell Signaling, #2465), cdc42 (Cell Signaling, #2466), and RhoA (Cell Signaling #2117).
Total RNA extraction and reverse transcription-PCR
Total RNA was isolated by a modified version of the single-step guanidinium thiocyanate method [22] (TRI REAGENT, T-9424, Sigma Chem. Co., St. Louis, MO, USA). Complementary DNA (cDNA) was prepared from the total RNA using a First Strand cDNA Synthesis Kit (Invitrogen, CA, USA). The level of de novo gene synthesis of each experimental group was measured by reverse transcriptase-polymerase chain reaction (RT-PCR). The primers pairs used and the annealing temperature were BDNF (Forward 5′-TGG CTG ACA CTT TCG AAC AC-3′; Reverse 5′-CCT CAT GGA CAT GTT TGC AG-3′; 51.8 °C), TrkB (Forward 5′-AGG GCA ACC CGC CCA CGG AA-3′; Reverse 5′-GGA TCG GTC TGG GGA AAA GG-3′; 56 °C), COX2 (Forward 5′-GCT GAG CCA TAC AGC AAA TCC-3′; Reverse 5-’ GGG AGT CGG GCA ATC ATC AG- 3′; 55 °C), MMP2 (Forward 5′-GCT GGC TGC CTT AGA ACC TTT C-3′; Reverse 5′-GAA CCA TCA CTA TGT GGG CTG AGA-3′; 57 °C), MMP9 (Forward 5′-GCA CGA CGT CTT CCA GTA CC-3′; Reverse 5′-GCA CTG CAG GAT GTC ATA GGT-3′; 55 °C), MMP13 (Forward 5′-GAC TTC CCA GGA ATT GGT GA-3′; Reverse 5′-TGA CGC GAA CAA TAC GGT TA-3′; 50 °C), eNOS (Forward 5′-CCC TTC AGT GGC TGG TAC AT-3′; Reverse5’-TAT CCA GGT CCA TGC AGA CA-3′; 52 °C), VEGFA (Forward 5′-CTT GCC TTG CTG CTC TAC C-3′; Reverse 5′-CAC ACA GGA TGG CTT GAA G-3′; 55 °C) and VEGFR2 (Forward 5′-GTG ACC AAC ATG GAG TCG TG-3′; Reverse 5′-CCA GAG ATT CCA TGC CAC TT-3′; 55 °C), all of which were obtained commercially. Any possible contamination of the PCR components was excluded by performing a PCR reaction with these components in the absence of the RT product (non-template control, NTC) and this was carried out for each set of experiments. Quantification of the RNA transcripts were expressed as mean + SEM by relating the mRNA data to the same data for various housekeeping genes using the formula A (target gene)/B (endogenous gene) = 2 –∆CT. All samples were analyzed using either three or four independent experiments.
Statistics
Data are expressed as the mean ± SEM. Differences between groups at a given time/dose point were identified by one-way ANOVA, which was followed by Dunnet’s post hoc test. Statistical comparisons between two independent groups were determined by the Mann-Whitney U test or the Student’s t test as appropriate. A p value of <0.05 was considered statistically significant compared to the vehicle or the no treatment group.
Results
We measured the BDNF level in the cultured media of various different breast cancer cell lines and the results showed that the MDA-MB-231 cells, but not the various other cell types, secrete BDNF into the culture media in a time-dependent manner (Fig. 2a). When analyzed by migration assay, the increase in migratory activity induced by administration of the 2-day-culture medium obtained from MDA-MB-231 cells was able to be blocked by pretreatment with neutralization antibody against BDNF, but not by non-specific antibody (Fig. 2b, c). The results therefore suggest that BDNF promotes cell migration by the MDA-MB-231 cell line.
To investigate the effects of Chinese herbal extracts on BDNF secretion, nine common CHEs were administrated to MDA-MB-231 cells for 24 h and the BDNF level in culture media were measured by ELISA. The results showed that A. membranaceous, P. lactiflora, L. chuanxiong, P. suffruticosa, and L. lucidum extracts were able to significantly increase BDNF secretion (Fig. 3a). If the measurements are normalized against the cell number for CHE treatment, only P. lactiflora, L. chuanxiong, and L. lucidum extracts show a significant increase in BDNF secretion (Fig. 3b) as well as a stimulation of the migratory activity (Fig. 3c) of the MDA-MB-231 cell line. Among these herbs, P. lactiflora, L. chuanxiong, and P. suffruticosa also showed an increase in the invasive activity (Fig. 3d), which suggests that these herbal extracts have the ability to promote the metastatic potential of the cancer cells.
Next, we examined the effects of the CHEs on the BDNF autoregulation loop of the MDA-MB-231 cell line. To do this, the gene expression levels of BDNF and TrkB in the cultured cells were analyzed. The results show that A. membranaceous, L. chuanxiong, and L. lucidum were able to significantly increase the expression of the BDNF protein by the MDA-MB-231 cell line. Furthermore, A. membranaceous, P. lactiflora, L. chuanxiong, and P. suffruticosa were able to significantly increase the expression of TrkB protein by the MDA-MB-231 cell line (Fig. 4a). In addition to the above, L. chuanxiong, and L. lucidum were able to up-regulate the expression of BDNF mRNA, while A. membranaceous, and L. chuanxiong were able to up-regulate the expression of NTF2 (TrkB) mRNA by the same cell line (Fig. 4b). Finally, there was found to be a correlation between BDNF and TrkB protein levels and between BDNF and TrkB mRNA levels in L. chuanxiong-treated cells. These results suggest that L. chuanxiong is able to modulate regulation via the BDNF-TrkB autocrine loop.
Next we investigated the effects of the CHEs on the expression of proteins that are involved in cell migration using MDA-MB-231 cells. The results showed that L. chuanxiong, P. suffruticosa, and L. lucidum increased p-Rac 1/2/3 protein expression (Fig. 5a), while P. lactiflora and L. chuanxion increased COX2 protein expression. Furthermore, A. membranaceous and L. chuanxiong, and L. lucidum significantly increased BDNF protein expression. Similarly, P. lactiflora increased MMP2 protein expression and A. membranaceous increased MMP9 protein expression (Fig. 5b). However, it should be noted that there was no significant change in the protein expression of various angiogenic factors, including VEGFA and VEGFR2, when the herb-treated cells were compared with the vehicle group (Fig. 5c). These results suggest that, while various herbs are able to induce cell migration and/or invasion, it would seem that none of the herbs are able to affect the angiogenic process. Taken together these findings suggest that there might be activation of a range of different signaling pathways by the individual herbal extracts.
To study in particular the role of BDNF-TrkB signaling in the context of the herb-induced responses produced by MDA-MB-231 cells, BDNF-neutralization antibody and TrkB inhibitor were used separately with L. chuanxiong extract to co-treat the MDA-MB-231 line. The results showed that L. chuanxiong (0.1-, 0.3-, 1 μg/mL) did not increase cell proliferation (Fig. 6a), but stimulated migratory activity (Fig. 6b), and that both anti-BDNF antibody and TrkB inhibitor, when used separately, were able to inhibit the induction of migratory activity by L. chuanxiong (Fig. 6c) using MDA-MB-231 cells. The L. chuanxiong induced increases in TrkB FL and BDNF expression were completely blocked by pretreatment with anti-BDNF antibody, while only TrkB, but not BDNF, expression was blocked by pretreatment with TrkB inhibitor (Fig. 6d, e). The results suggest that BDNF plays an important role in the L. chuanxiong induced BDNF-TrkB autocrine loop regulation found in MDA-MB-231 cells.
Since BDNF in its mature form is secreted into the culture media of MDA-MB-231, this protein has the potential to affect adjacent cells associated with metastasis such as endothelial cells, thus there is a possibility of a paracrine effect. Therefore next we attempted to determine using HUVEC cells what was the effect of CHEs on the BDNF paracrinal loop. The results show that, in HUVEC cells, L. lucidum significantly increased the level of BDNF protein while A. membranaceous, P. suffruticosa and L. lucidum significantly increased the level of TrkB protein (Fig. 7a). Furthermore, A. membranaceous and L. lucidum up-regulated the expression level of BDNF mRNA, while A. membranaceous, P. suffruticosa and L. lucidum up-regulated the expression level of NTF2 (TrkB) mRNA using the same cell line (Fig. 7b). The results suggest that A. membranaceous and L. lucidum are able to modulate BDNF-TrkB autocrine loop regulation present in HUVEC cells
Finally, the effect of CHEs on migratory protein expression by HUVEC cells was analyzed by Western blotting. The results showed that, using HUVEC cells, L. lucidum increased Rho protein expression (Fig. 8a) while P. lactiflora and L. chuanxiong increased COX2 protein expression (Fig. 8b). These findings suggest that these proteins are likely to have the ability to stimulate the migratory ability of endothelial cells.
Discussion
Cancer metastasis is a multistage process that requires interactions between cancer cells and non-malignant cells within the tumor microenvironment. In this article, the effect of the interaction between cancer cells (MDA-MB-231) and endothelial cells (HUVEC) on migratory potential was investigated. To our knowledge, we are the first to investigate the effect of Chinese herbal medicines on the BDNF-related metastatic potential of cancer-endothelial interactions. There is consensus that lipopolysaccharide contamination during herbal preparation might have an effect on the results of this type of experiment. To decrease such contamination effects, polymyxin B was administration routinely during each experiment [23]. The major limitation of this study is that only one dose of herbal extract was used. Furthermore, our previous study has shown that there was no cell cytotoxicity at the dose ranges used [18]. Nevertheless, further dose-related investigations on the herbs investigated in this study are mandatory, as well as being on going.
In this study, we found that BDNF affected not only MDA-MB-231 itself (an autocrine effect), but also affected HUVEC cells (a paracrine effect). The role of BDNF in the regulation of cell survival/growth has been described elsewhere regarding breast cancer [13], neuroblastoma and myeloma and these effects have been found to occur in both an autocrinal and a paracrinal manner [24, 25]. Accumulating evidence suggests that a reduction in the level of BDNF protein in specific areas of the brain provokes depressive-like behavior as well as affecting neurogenesis in vivo [26]. Recent investigations have demonstrated that some Chinese medicinal herbs have an antidepressant-like effect that occurs via an increase in the level of BDNF within the rat brain [27]. In addition, a compound herbal recipe (Kai-Xin-San), which is composed of Radix Panax ginseng, Rhizoma Smilacis Glabrae (Fu-Ling), Radix Polygalae (Yuan-Zhi) and Rhizoma Acori Tatarinowii (Shi-Chang-Pu), has been shown to increase BDNF expression and exerts a neuroprotective effect as well as an antidepressant-like effect via a synergistic mechanism that involves the multiple compounds present in this recipe [28].
For decades, there has been an increasing trend whereby patients with breast cancer seek integrative therapies that can include Chinese medicinal herbs with the aim of relieving their discomfort during cancer treatment. Although the role of BDNF in breast cancer remains controversial [14], it has become important to elucidate the effects of Chinese herbal medicines on BDNF production by cancer cells. In earlier studies, the secretion of MMPs has been proposed to make a significant contribution to the BDNF-induced cancer invasiveness of neuroblastoma and lung large cell neuroendocrine carcinoma [29, 30]. In addition to MMPs, cyclooxygenase-2 (COX-2) and prostaglandin E2 have also been shown to be involved in cancer development, angiogenesis and invasion. Previous investigations have also suggested that treatment with herbal extract can have an anticancer effect. One such example is Paeonol extract, which exerts an anticancer effect on colorectal cancer cells via an inhibition of PGE2 and COX-2 expression [31, 32]. There is consensus that the Rho A family and CDC42-Rac signaling, play independent roles in the various stages of actin reorganization, while COX2 and MMPs are involved in tumor invasion by many cancer types. Our findings indicate that the various herbal extracts are able to promote cell migration and/or invasion, which leads us to speculate that these herbal responses might occur via the activation of a number of distinct signaling pathways. It should be noted that there are corresponding changes in the levels of BDNF and TrkB at the protein level and BDNF and TrkB at the mRNA transcript level when cells are treated with L. chuanxiong, while there is a trend towards a correlation between these levels when cells are treated with A. membranaceous- and L. lucidum. The discrepancies found with the other herbal treatments may be due to the synergistic and/or antagonistic properties of the various different chemical compounds found in such herbal extracts. The complex mixture of chemicals present is very likely to induce complex mixture of drug-drug, cell-cell, and drug-cell interactions. In addition to the above, there are also a range of different responses when migratory protein expression levels were examined after treatment with the various herbal extracts when the MDA-MB-231 and HUVEC cell lines were compared. These cell lines have different embryonic origins and it is reasonable that there should be distinct and cell-specific responses to a given treatment when these different cell types are investigated.
There is consensus that angiogenesis plays an important role in cardioprotection. Recent studies have showed that an extract of A. membranaceus not only increases cell proliferation, migration and tube formation [33], but also that it has been found to affect nitric oxide production, a key regulator of angiogenesis, via the JAK2/STAT3 and ERK1/2 pathways in human endothelial HUVEC cells [34]. In addition to the above, there is evidence that BDNF induces the migration of endothelial cells via the BDNF-TrkB signaling pathway [35]. Our findings show that not only L. lucidum, but also A. membranaceous, is able to increase the level of TrkB protein in HUVEC cells and, furthermore, such treatment also up-regulate BDNF and NTF2 (TrkB) mRNA levels in the same cells, which might also explain the above-mentioned A. membranaceous effects.
Conclusions
In summary, we have demonstrated that many Chinese medicinal herbs are able to enhance BDNF-TrkB signaling in both an autocrine and a paracrine manner. These findings provide important information that should help with the development of better integrative medical therapies that can be used by patients during the treatment of breast cancer.
Acknowledgments
We are in debt to Miss Chiu, LC for her technical assistance and Dr. Ralph Kirby for the manuscript editing.
Funding
This work was supported by grants from Taipei Veterans General Hospital (V104C-015, V105C-018), Ministry of health and welfare (Center of Excellence for Cancer Research at Taipei Veterans General Hospital phase II) (MOHW103-TD-B-111-02, MOHW104-TDU-B-211-124-001) and Cheng-Hsin Yang-Ming project (CY10411).
Availability of data and materials
All data generated or analysed during this study are included in this published article.
Abbreviations
- BDNF
Brain-Derived Neurotrophic Factor
- CHE
Chinese herbal extracts
- HUVEC
Human umbilical vein endothelial cell
- MMPs
Matrix metalloproteinase
- TNBC
Triple negative breast cancer
Additional file
Authors’ contributions
JH and LM formed the idea and supervised the studies. FP provided the knowledge of herbal medicine. MT performed the experiments and analyzed the data. YF and YM provided clinical comments and provided experimental facilities. JH wrote the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
not applicable.
Consent for publication
not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Footnotes
Electronic supplementary material
The online version of this article (doi:10.1186/s12906-017-1909-7) contains supplementary material, which is available to authorized users.
Contributor Information
Jen-Hwey Chiu, Email: chiujh@mailsrv.ym.edu.tw.
Fang-Pey Chen, Email: fpchen@vghtpe.gov.tw.
Yi-Fang Tsai, Email: yftsai@vghtpe.gov.tw.
Man-Ting Lin, Email: frmt1225@gmail.com.
Ling-Ming Tseng, Email: lmtseng@vghtpe.gov.tw.
Yi-Ming Shyr, Email: ymshyr@vghtpe.gov.tw.
References
- 1.Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2014; [DOI] [PubMed]
- 2.Ministry of Health and Welfare, Executive Yuan, Taiwan, Republic of China: Annual Report: 100, 2014.
- 3.Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4(3):209–229. doi: 10.1016/j.molonc.2010.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi: 10.1172/JCI45014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015;14(3):769–778. doi: 10.1158/1535-7163.MCT-14-0926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roche H, Mesleard C, Arnould L, Lemonnier J, et al. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial. Future Oncol. 2015;11(16):2283–2297. doi: 10.2217/fon.15.102. [DOI] [PubMed] [Google Scholar]
- 7.Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26(11):1810–1816. doi: 10.1200/JCO.2007.14.5375. [DOI] [PubMed] [Google Scholar]
- 8.Acheson A, Conover JC, Fandl JP, DeChiara TM, Russell M, Thadani A, Squinto SP, Yancopoulos GD, Lindsay RM. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature. 1995;374(6521):450–453. doi: 10.1038/374450a0. [DOI] [PubMed] [Google Scholar]
- 9.Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013;14(6):401–416. doi: 10.1038/nrn3505. [DOI] [PubMed] [Google Scholar]
- 10.Lawn S, Krishna N, Pisklakova A, Qu X, Fenstermacher DA, Fournier M, Vrionis FD, Tran N, Chan JA, Kenchappa RS, et al. Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. J Biol Chem. 2015;290(6):3814–3824. doi: 10.1074/jbc.M114.599373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sinkevicius KW, Kriegel C, Bellaria KJ, Lee J, Lau AN, Leeman KT, Zhou P, Beede AM, Fillmore CM, Caswell D, et al. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci U S A. 2014;111(28):10299–10304. doi: 10.1073/pnas.1404399111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Yang X, Martin TA, Jiang WG. Biological influence of brain-derived neurotrophic factor on breast cancer cells. Int J Oncol. 2012;41(4):1541–1546. doi: 10.3892/ijo.2012.1581. [DOI] [PubMed] [Google Scholar]
- 13.Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X, Hondermarck H. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 2011;17(7):1741–1752. doi: 10.1158/1078-0432.CCR-10-1890. [DOI] [PubMed] [Google Scholar]
- 14.Huth L, Rose M, Kloubert V, Winkens W, Schlensog M, Hartmann A, Knuchel R, Dahl E. BDNF is associated with SFRP1 expression in luminal and basal-like breast cancer cell lines and primary breast cancer tissues: a novel role in tumor suppression? PLoS One. 2014;9(7):e102558. doi: 10.1371/journal.pone.0102558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Davis SR, Lijovic M, Fradkin P, Bradbury J, La China M, Schwarz M, Bell RJ. Use of complementary and alternative therapy by women in the first 2 years after diagnosis and treatment of invasive breast cancer. Menopause. 2010;17(5):1004–1009. doi: 10.1097/gme.0b013e3181d991dd. [DOI] [PubMed] [Google Scholar]
- 16.Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer--a systematic review. Nutr Cancer. 2015;67(3):373–391. doi: 10.1080/01635581.2015.1004731. [DOI] [PubMed] [Google Scholar]
- 17.Lin YH, Chiu JH. Use of Chinese medicine by women with breast cancer: a nationwide cross-sectional study in Taiwan. Complement Ther Med. 2011;19(3):137–143. doi: 10.1016/j.ctim.2011.04.001. [DOI] [PubMed] [Google Scholar]
- 18.Chiu JH, Chang CJ, Wu JC, Liu HJ, Wen CS, Hsu CH, Chen JL, Tseng LM, Chen WS, Shyr YM. Screening to identify commonly used Chinese herbs that affect ERBB2 and ESR1 gene expression using the human breast cancer MCF-7 cell line. Evid Based Complement Alternat Med. 2014;2014:965486. doi: 10.1155/2014/965486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Chen JL, Wang JY, Tsai YF, Lin YH, Tseng LM, Chang WC, King KL, Chen WS, Chiu JH, Shyr YM. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab. Menopause. 2013;20(6):646–654. doi: 10.1097/gme.0b013e31827b2240. [DOI] [PubMed] [Google Scholar]
- 20.Tsai CH, Chiu JH, Yang CW, Wang JY, Tsai YF, Tseng LM, Chen WS, Shyr YM. Molecular characteristics of recurrent triple-negative breast cancer. Mol Med Rep. 2014;12:7326–7334. doi: 10.3892/mmr.2015.4360. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
- 22.Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–159. doi: 10.1016/0003-2697(87)90021-2. [DOI] [PubMed] [Google Scholar]
- 23.Cardoso LS, Araujo MI, Goes AM, Pacifico LG, Oliveira RR, Oliveira SC. Polymyxin B as inhibitor of LPS contamination of Schistosoma Mansoni recombinant proteins in human cytokine analysis. Microb Cell Factories. 2007;6:1. doi: 10.1186/1475-2859-6-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005;105(11):4429–4436. doi: 10.1182/blood-2004-08-3096. [DOI] [PubMed] [Google Scholar]
- 25.Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–216. doi: 10.1038/nrc1014. [DOI] [PubMed] [Google Scholar]
- 26.Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116–1127. doi: 10.1016/j.biopsych.2006.02.013. [DOI] [PubMed] [Google Scholar]
- 27.Xue W, Zhou X, Yi N, Jiang L, Tao W, Wu R, Wang D, Jiang J, Ge X, Wang Y, et al. Yueju pill rapidly induces antidepressant-like effects and acutely enhances BDNF expression in mouse brain. Evid Based Complement Alternat Med. 2013;2013:184367. doi: 10.1155/2013/184367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Hu Y, Zhou XJ, Liu P, Dong XZ, Mu LH, Chen YB, Liu MY, Yu BY. Antidepressant and neuroprotective effect of the Chinese herb kaixinsan against lentiviral shRNA knockdown brain-derived neurotrophic factor-induced injury in vitro and in vivo. Neuropsychobiology. 2014;69(3):129–139. doi: 10.1159/000358089. [DOI] [PubMed] [Google Scholar]
- 29.Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L. The neurotrophin receptor TrkB cooperates with c-met in enhancing neuroblastoma invasiveness. Carcinogenesis. 2005;26(12):2105–2115. doi: 10.1093/carcin/bgi192. [DOI] [PubMed] [Google Scholar]
- 30.Odate S, Nakamura K, Onishi H, Kojima M, Uchiyama A, Nakano K, Kato M, Tanaka M, Katano M. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79(3):205–214. doi: 10.1016/j.lungcan.2012.12.004. [DOI] [PubMed] [Google Scholar]
- 31.Li M, Tan SY, Wang XF. Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE(2) synthesis and COX-2 expression. Oncol Rep. 2014;32(6):2845–2853. doi: 10.3892/or.2014.3543. [DOI] [PubMed] [Google Scholar]
- 32.Tu HP, Fu MM, Kuo PJ, Chin YT, Chiang CY, Chung CL, Fu E. Berberine's effect on periodontal tissue degradation by matrix metalloproteinases: an in vitro and in vivo experiment. Phytomedicine. 2013;20(13):1203–1210. doi: 10.1016/j.phymed.2013.06.001. [DOI] [PubMed] [Google Scholar]
- 33.Zhang L, Yang Y, Wang Y, Gao X. Astragalus Membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury. Die Pharmazie. 2011;66(2):144–150. [PubMed] [Google Scholar]
- 34.Wang SG, Xu Y, Chen JD, Yang CH, Chen XH. Astragaloside IV stimulates angiogenesis and increases nitric oxide accumulation via JAK2/STAT3 and ERK1/2 pathway. Molecules. 2013;18(10):12809–12819. doi: 10.3390/molecules181012809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Matsuda S, Fujita T, Kajiya M, Takeda K, Shiba H, Kawaguchi H, Kurihara H. Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin alphaVbeta3-FAK cascade. J Cell Physiol. 2012;227(5):2123–2129. doi: 10.1002/jcp.22942. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analysed during this study are included in this published article.